About theravance biopharma inc - TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the following geographical segments: U.S. and Europe. The company was founded in July 2013 and is headquartered in South San Francisco, CA.
TBPH At a Glance
Theravance Biopharma, Inc.
901 Gateway Boulevard
South San Francisco, California 94080
| Phone | 1-650-808-6000 | Revenue | 107.46M | |
| Industry | Pharmaceuticals: Major | Net Income | 105.90M | |
| Sector | Health Technology | 2025 Sales Growth | 66.919% | |
| Fiscal Year-end | 12 / 2026 | Employees | 90 | |
| View SEC Filings |
TBPH Valuation
| P/E Current | 7.411 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.101 |
| Price to Sales Ratio | 8.968 |
| Price to Book Ratio | 3.22 |
| Price to Cash Flow Ratio | 4.04 |
| Enterprise Value to EBITDA | -93.628 |
| Enterprise Value to Sales | 6.736 |
| Total Debt to Enterprise Value | 0.104 |
TBPH Efficiency
| Revenue/Employee | 1,194,044.444 |
| Income Per Employee | 1,176,611.111 |
| Receivables Turnover | 1.125 |
| Total Asset Turnover | 0.256 |
TBPH Liquidity
| Current Ratio | 10.925 |
| Quick Ratio | 10.925 |
| Cash Ratio | 8.233 |
TBPH Profitability
| Gross Margin | 94.868 |
| Operating Margin | -12.326 |
| Pretax Margin | 120.27 |
| Net Margin | 98.54 |
| Return on Assets | 25.221 |
| Return on Equity | 44.845 |
| Return on Total Capital | 28.449 |
| Return on Invested Capital | 36.774 |
TBPH Capital Structure
| Total Debt to Total Equity | 25.444 |
| Total Debt to Total Capital | 20.283 |
| Total Debt to Total Assets | 15.548 |
| Long-Term Debt to Equity | 21.755 |
| Long-Term Debt to Total Capital | 17.343 |